/ /

  • linkedin
  • Increase Font
  • Sharebar

    SGLT2 Inhibitors Improve HF, Survival in Clinical T2D Population

    In late 2015, authors of the multicenter Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes trial (EMPA-REG OUTCOME) reported that at 3.1 years of follow-up, empagliflozin (vs placebo) was associated with a reduction in CV mortality, nonfatal MI, or nonfatal stroke as well as reductions in all-cause and CV mortality.

    The Comparative Effectiveness of Cardiovascular Outcomes in New Users of SGLT-2 Inhibitors (CVD-REAL) study was designed to assess the potential for a class effect on CV outcomes for the currently approved SGLT-2 inhibitors empagliflozin, canagliflozin, and dapagliflozin.

    Primary outcome measures: incidence of hospitalizations for heart failure (from index date to one year)

    Secondary outcome measures: Incidence of all-cause mortality

    Results were presented at the American College of Cardiology 2017 Scientific Sesssions on March 19, 2017 in Washington, DC. 

    Click through this brief slide show for highlights of the results.


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available